Trinity Biotech plc (TRIB)
| Market Cap | 12.25M -14.5% |
| Revenue (ttm) | 43.79M -28.9% |
| Net Income | -37.38M |
| EPS | -2.00 |
| Shares Out | 20.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,459 |
| Open | 0.6053 |
| Previous Close | 0.6251 |
| Day's Range | 0.6053 - 0.6053 |
| 52-Week Range | 0.5012 - 3.4400 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | 15.00 (+2,378.93%) |
| Earnings Date | May 6, 2026 |
About TRIB
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, v... [Read more]
Financial Performance
In 2025, Trinity Biotech's revenue was $43.79 million, a decrease of -28.87% compared to the previous year's $61.56 million. Losses were -$37.38 million, 17.6% more than in 2024.
Financial StatementsNews
Trinity Biotech files to sell 167.95M American depositary shares
The 167.95M American depositary shares represent 3.36M ordinary shares.
Trinity Biotech Registration statement: Registration filing
Trinity Biotech filed a registration statement on May 13, 2026, providing details about a securities offering with the SEC.
Trinity Biotech Registration statement: Registration filing
Trinity Biotech filed a registration statement on May 13, 2026, providing details about a securities offering with the SEC.
Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
- Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces further operational progress in its Comprehensive Transfo...
Trinity Biotech Annual report: Q4 2025
Trinity Biotech has published its Q4 2025 annual report on April 30, 2026.
Trinity Biotech Slides: Q4 2025
Trinity Biotech has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on April 30, 2026.
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
DUBLIN and NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a global diagnostics company, today announced successful results from a clinical study of a new, enhanced ve...
Trinity Biotech announes collaboration agreement with University at Buffalo
Trinity Biotech (TRIB) announced it has entered into a collaboration agreement with the University at Buffalo, New York, or UB. The partnership focuses on advancing and commercializing a suite of…
Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome
DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, inc...
Trinity Biotech begins rollout of glucose monitoring system in Brazil
Trinity Biotech (TRIB) has commenced the commercial rollout in Brazil of its updated laboratory blood glucose monitoring solution, the next-generation HbA1c column system for its Premier Hb9210 platfo...
Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System
Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech pl...
Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
DUBLIN and WILSONVILLE, Ore., March 11, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solut...
Trinity Biotech announces advancements in CGM system development
John Gillard, CEO, commented: “These are some of the most important technical advancements to date in our CGM+ development program. The glucose measurement accuracy gains achieved by the incorporation...
Trinity Biotech says continuing to focus on Comprehensive Transformation Plan
The company said, “The Company’s key strategic objectives are to grow the existing business profitably and to advance its exciting innovation agenda, including the flagship development CGM+. As such, ...
Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
- Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics ar...
Trinity Biotech sees Q4 revenue $11.5M-$12.5M vs. $15.9M last year
The company said, “The reduction in revenue between Quarter 4, 2024 and Quarter 4, 2025 was primarily driven by:The residual impact of the disruption to the global health market for…
Trinity Biotech Provides Business and Trading Update
DUBLIN, March 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearab...
Trinity Biotech files to sell 35.28M American Depositary Shares for holders
09:12 EST Trinity Biotech (TRIB) files to sell 35.28M American Depositary Shares for holders
Trinity Biotech secures $25M standby equity purchase agreement
Trinity Biotech (TRIB) has entered into a $25M Standby Equity Purchase Agreement with an affiliate of financing partner Yorkville Advisors Global. The agreement provides Trinity Biotech with an additi...
Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives
- Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innova...
Trinity Biotech Registration statement: Registration filing
Trinity Biotech filed a registration statement on February 25, 2026, providing details about a securities offering with the SEC.
Trinity Biotech receives noncompliance notification from Nasdaq
Trinity Biotech (TRIB) received notice from Nasdaq that the company no longer meets the requirement in Nasdaq Listing Rule 5450 that listed securities maintain a minimum market value of publicly…
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Trinity Biotech receives noncompliance notification from Nasdaq
Trinity Biotech (TRIB) received notice from Nasdaq that the company is not in compliance with Nasdaq Listing Rule 5450, requiring that listed securities maintain a minimum bid price of $1.00…
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement
DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...